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Abstract
Methamphetamine (METH) is an addictive psychostimulant whose societal impact is on the rise. Emerging evidence
suggests that psychostimulants alter synaptic plasticity in the brain—which may partly account for their adverse effects.
While it is known that METH increases the extracellular concentration of monoamines dopamine, serotonin, and
norepinephrine, it is not clear how METH alters glutamatergic transmission. Within this context, the aim of the present study
was to investigate the effects of acute and systemic METH on basal synaptic transmission and long-term potentiation (LTP;
an activity-induced increase in synaptic efficacy) in CA1 sub-field in the hippocampus. Both the acute ex vivo application of
METH to hippocampal slices and systemic administration of METH decreased LTP. Interestingly, the acute ex vivo application
of METH at a concentration of 30 or 60 mM increased baseline synaptic transmission as well as decreased LTP. Pretreatment
with eticlopride (D2-like receptor antagonist) did not alter the effects of METH on synaptic transmission or LTP. In contrast,
pretreatment with D1/D5 dopamine receptor antagonist SCH23390 or 5-HT1A receptor antagonist NAN-190 abrogated the
effect of METH on synaptic transmission. Furthermore, METH did not increase baseline synaptic transmission in D1
dopamine receptor haploinsufficient mice. Our findings suggest that METH affects excitatory synaptic transmission via
activation of dopamine and serotonin receptor systems in the hippocampus. This modulation may contribute to synaptic
maladaption induced by METH addiction and/or METH-mediated cognitive dysfunction.
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Introduction
Methamphetamine (METH) is one of the most addictive drugs
in existence. The illicit use of METH is a serious societal and
public health problem that is rapidly accelerating [1]. Indeed, the
2006 Treatment Episode Dataset indicates the percentage of
addiction treatment admissions due to METH/amphetamine
abuse has risen from three percent in 1996 to nine percent in 2006
[2]. Although METH can be prescribed (to be taken PO, by
mouth) to treat ADHD and obesity, drug abusers administer much
larger doses [3], through faster administration routes than those
used clinically. Sixty-five percent of those admitted for METH/
amphetamine abuse reported smoking as the route of administra-
tion, eighteen percent reported injection, and 11 percent reported
inhalation, [2]. The adverse effects of METH abuse are both short
(e.g., cardiac arrhythmias, hyperthermia, insomnia, confusion
[4,5] and long-term (e.g., neurotoxicity, psychosis, cognitive
impairments, addiction, changes in brain structure and function
[3,6,7]. The neural mechanisms that underlie these behavioral
responses are not completely known. Lack of such knowledge
impedes evidence-based development of pharmacological inter-
vention not only to treat addiction, but also to reverse damage
caused by methamphetamine use.
METH is a substrate for the dopamine transporter and
profoundly increases the concentration of extracellular mono-
amines dopamine (DA), serotonin (5-HT), and norepinephrine
(NE) by redistributing these neurotransmitters from synaptic
vesicles to the cytosol, in addition to inducing reverse transport
and competing for transmitter uptake at their cognate transporters
[8]. METH also affects extracellular glutamate levels [9,10,11].
METH is pharmacokinetically distinct from other psychostimu-
lants- its effects are longer lasting compared to other psychostim-
ulants such as cocaine and amphetamine, with a plasma half-life in
humans of approximately 12 hours [12,13]. Likely due to its
lipophilicity, METH is widely distributed in the human and rat
brain, a property it does not share with other psychostimulants
such as cocaine [14,15,16].
The functional states of the hippocampus are under the control
of many neuromodulators, including DA, 5-HT and NE. This
mnemonic cortical structure receives DA input from the ventral
tegmental area [17], NE input from the locus coeruleus [18], and
5-HT input from the raphe nuclei [19]. Although the hippocam-
pus is not commonly thought to be involved in addictive
behaviors, recent evidence demonstrates its involvement in
psychostimulant responses and addiction. Activation of the
subiculum (the main output of the hippocampal formation) has
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behavior [20]. Indeed, it has recently been discovered that rats will
self-administer METH directly into their hippocampus [21].
Developmental disruption of hippocampal connectivity results in
increased self-administration of cocaine [22] and METH [23].
Hippocampal synaptic plasticity is bi-directionally modulated by
cocaine self-administration [24]. Inactivation of hippocampal
output attenuates cocaine seeking elicited by associative cues, as
well as by cocaine injection [25,26]. Because the hippocampus is
implicated in the reinstatement of psychostimulant self-adminis-
tration, and may even contribute to the rewarding properties of
METH [21], it is critical to study the potential effects of METH in
this brain region.
Drugs of abuse, including METH, can cause long-lasting
changes in neuronal systems [27,28], and alter synaptic plasticity
[29,30]. There have been a number of reports on the effects of
cocaine on hippocampal synaptic transmission [24,31,32,33,
34,35], and although there are some reports concerning the
effects of METH on synaptic transmission in the striatum [36] and
hippocampus [37], the specific nature and pharmacology of
METH-evoked changes in hippocampal plasticity are ill-defined.
Here we examined the systemic and acute effects of METH on
baseline synaptic transmission and long-term potentiation (LTP) in
the CA1 region of the hippocampus. LTP is the potentiation of
synapses caused by an induction event, such as high frequency
stimulation, and is a ubiquitous model for studying long-lasting
changes in the nervous system [38,39,40,41,42]. We discovered
that acute ex vivo application of METH increased baseline
excitatory synaptic transmission and decreased LTP at CA1
synapses. Furthermore, systemic administration of METH also
decreased LTP. Our findings suggest that the effects of acutely
applied METH on synaptic transmission appear to be mediated
through the activation of both serotonergic and dopaminergic
receptor systems. Some of this work has been published in abstract
form [43].
Methods
Mice
(JAX: C57BL/6J) were housed in the AAALAC-certified animal
care facility (ACF) at Meharry Medical College. Mice were
maintained in an environment with ambient temperature between
22–24.5uC with a 12:12-hour light/dark cycle and ad libitum
access to food and water. For each experimental treatment mice
were randomly assigned to different treatment groups. All
experimental procedures complied with the NIH Guide for the
Care and Use of Laboratory Animals, and were conducted with
the approval of the Meharry Medical College Institutional Animal
Care and Use Committee.
Mutant mice
D1 and D5 receptor mutant mice extensively backcrossed onto
C57BL/6J were obtained from Dr. Gregg Stanwood (Department
of Pharmacology, Vanderbilt University Medical Center, Nash-
ville, TN). The electrophysiological experimenter was blind to
genotype. Genotype was determined before and reconfirmed by
PCR after electrophysiological assessment using a previously
described method [44].
Slice preparation
Acutely prepared hippocampal slices (400 mm) were obtained
from anesthetized (Isoflurane) adult (2–4 months of age) mice.
Transverse brain slices were dissected in ice cold, oxygenated
(95% O2/5% CO2) artificial cerebrospinal fluid (aCSF) containing
(mM): NaCl (125), KCL (2.5), KH2PO4 (1.25), MgSO4 (1.2),
CaCl2 (2), NaHCO3 (25), and dextrose (10). The CA3 region was
surgically removed from all slices (Fig. 1A). Slices were then
transferred to a submerged recording chamber, which continu-
ously superfused aCSF (saturated with 95% O2/5% CO2) at a rate
of 1.5 ml/minute, with temperature maintained at 30uC. The
slices were allowed to recover from dissection for at least an hour
in the recording chamber before experiments were begun.
Extracellular recording
Extracellular recording electrodes (borosilicate glass, ,1 mm tip)
filled with aCSF were placed in the stratum radiatum of CA1. We
chose to assess field excitatory post-synaptic potentials (fEPSPs)
because they provide a reliable and stable measure of excitatory
synaptic transmission. Dendritic fEPSP responses were evoked
with a bipolar tungsten stimulating electrode (Rhodes, Inc) placed
on either the CA3 or the subicular side of the recording electrode
in the stratum radiatum. Responses were amplified using the
Axoclamp-2A amplifier (Molecular Devices, Inc). The electrical
stimulus consisted of a single square waveform of 0.3 msec
duration given at intensities of 10–130 mA generated by a Grass
S88 stimulator equipped with stimulus isolation unit PSIU6.
Data acquisition and analysis
Data were acquired with Clampex 10 and analyzed with
Clampfit 10 software (Molecular Devices). The initial slope of the
fEPSP (which provides a measure of the strength of excitatory
synaptic transmission) was measured by fitting a straight line to the
first millisecond of the fEPSP immediately following the fiber
volley, and was monitored in real-time in every experiment. A
stimulus-response curve was then determined using stimulation
intensities between 10–130 mA. Baseline stimulation parameters
were selected to evoke a response of 40–60% of the maximum
slope. Baseline stimulation was then commenced at a frequency of
0.033 Hz for the entire length of the experiment. The paired-pulse
protocol used in the systemic METH experiments consisted of two
pulses at baseline intensity separated by 50 milliseconds. Control
synaptic responses were normalized by dividing all slopes by the
average of the 10 fEPSP slopes 5 minutes pre-tetanus. Since high
dose METH caused a transient increase in baseline synaptic
transmission, high dose METH synaptic responses were normal-
ized by dividing all slopes by the average of the 10 fEPSP slopes 5
minutes pre-METH application. SCH23390 + METH responses
were normalized by dividing all slopes by the average of the 10
fEPSP slopes 5 minutes pre-SCH23390 application. The tetanus
event in the acute drug application studies consisted of four
100 Hz pulses with a 30 second inter-stimulus interval. The
tetanus event in the systemic studies consisted of three 100 Hz
pulses with a 30 second inter-stimulus interval. LTP was quantified
as the normalized fEPSP response at 55–60 minutes post-tetanus.
All baseline value comparisons were made 15–20 minutes post-
drug application. Collected data was analyzed for statistical
significance with an unpaired t-test, a paired t-test, or a one-way
ANOVA followed by a Fisher’s LSD post-hoc test, where
applicable.
Drug application
Drugs used in this project are commercially available (except for
METH) from Tocris or Sigma-Aldrich. In all cases drugs were
added to the aCSF for perfusion to slices. In METH only
experiments, the drug was applied at t=25 and washed out at
t=57, with tetanus at t=55. Drug free control experiments for
METH treated slices were also tetanized at t=55. In co-
application experiments, the first drug was applied at t=25, the
METH Reduces LTP
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11382Figure 1. At lower concentrations, METH decreases LTP. At higher concentrations, METH increases baseline synaptic transmission and
decreases LTP. (A) Summary plot of normalized fEPSP slope measurements recorded in the CA1 region of the hippocampus. Blue diamonds show
results from drug free slices (A), red triangles (B–F) are from METH-treated slices. Error bars show 6 SEM. Insets are 30-msec sweeps taken from
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In control experiments for METH co-application experiments,
drug was added at t=25 and washed out at t=87, with tetanus at
t=85. Slices taken from animals administered METH i.p. were
tetanized at t=25, and were not exposed to METH in the
recording chamber.
Systemic administration of METH
Mice were injected with 10 mg/kg METH i.p. twice daily, at 7
AM and 7 PM for five days. Mice were then sacrificed for LTP
assessment approximately 16 hours after their last injection of
methamphetamine. No drugs were applied to slices taken from the
systemic-exposed animals.
Results
METH augments baseline synaptic transmission and
attenuates LTP
Using ex vivo slice preparations derived from the CA1 region of
the mouse hippocampus, we first assessed the impact of METH on
synaptic plasticity. After establishing fEPSPs (average amplitude at
baseline for all experiments was ,2 mV, see sweeps in Fig. 1), we
examined the effects of acute METH application on LTP. METH
was administered to the slices over the range of 0.1–60 mM. The
rationale for these particular concentrations derives from previous
in vivo studies demonstrating that a 4 mg/kg i.p. injection of
METH results in a concentration of about 10 mM in the mouse
brain [45], whereas a 1 mg/kg i.v. infusion also results in a similar
concentration in rats [46]. For humans, a dose of 30 mg i.v. is
estimated to result in a concentration of 14 mM in the brain [14].
METH abusers commonly inject dosages of tens to hundreds of
milligrams [3]; therefore, we investigated a wide range of METH
concentrations that included low and high concentrations of
METH that are within a clinically-relevant concentration range.
In drug-free control slices, we observed that robust LTP was
produced and maintained throughout the 60-min post tetanus.
LTP magnitude 55–60 minutes post-tetanus in control slices was
1.826.08 [n=10(5)] (all n values are represented in the format
[n= number of slices (number of animals)]) (Fig. 1A). METH
significantly decreased LTP compared to control at concentrations
$0.1 mM (Fig. 1). At 30 mM and 60 mM, METH also increased
baseline synaptic transmission. As shown in Fig. 1E, the magnitude
of baseline synaptic responses in the apical dendritic area of the
CA1, measured as changes to the fEPSP slope, increased during a
30 min application of 30 mM METH. The magnitude of
normalized fEPSPs 15–20 minutes after 30 mM METH applica-
tion (t=20–25 compared to t=40–45) was significantly increased
to 1.126.01 [n=15(4)] (Fig. 1E, P,0.05), the fEPSP slope
increased from 21.156.10 to 21.296.11 millivolts/millisecond
(P,.001, paired t-test). The magnitude of normalized fEPSPs 15–
20 minutes after 60 mM METH application (t=20–25 compared
to t=40–45) was significantly increased to 1.206.05 [n=4(2)]
(Fig. 1F, P,0.05). These changes in synaptic transmission
observed at 30 mM and 60 mM METH did not occur at lower
drug concentrations (Fig. 1A–D). Our data demonstrates that
METH can increase glutamatergic transmission in the absence of
tetanic stimulation. Since both 30 mM and 60 mM METH
produced consistent and significant effects on both synaptic
transmission and LTP, we chose to use the more clinically
relevant concentration of 30 mM in all subsequent acute-exposure
experiments.
METH increases baseline synaptic transmission in the
absence of electrical stimulation
METH-induced increase in synaptic transmission is
transient. Some forms of plasticity require glutamatergic
activation [47]. To assess whether the observed increase of
baseline synaptic transmission we observed was dependent on
glutamatergic activation, we assessed the effect of 30 mM METH
on fEPSPs with the stimulator turned off during the first 15
minutes of drug application. Under these conditions, METH
increased fEPSPs 15–20 minutes after drug was added to the
perfusion bath (Fig. 2A). Following a wash out period (as in Fig. 1,
but without tetanus) we found that the effect on synaptic
transmission is transient, decreasing to pre-drug baseline within
,60 minutes (Fig. 2A). These results indicate that the correct
normalization point for studies where METH induces an increase
in synaptic transmission is before METH application, since the
effect is gone within 60 min.
The effects of METH on baseline synaptic transmission
are not altered by blockade of NMDA receptors
LTP induction in the CA1 region of the hippocampus is
predominantly mediated by NMDA receptors [48,49,50]. It has
also been observed that METH enhances NMDA-mediated
synaptic transmission [51]. To examine the possible involvement
of NMDA receptors in our observed METH-induced increase in
baseline synaptic transmission, we applied METH to slices
pretreated with 50 mM of the NMDA receptor antagonist dl-2-
amino-5-phosphonovaleric acid (DL-APV), a concentration shown
previously to block NMDA-mediated currents [52]. DL-APV
applied alone did not change fEPSP slopes (Fig. 2B) or affect the
ability of METH (30 mM) to increase excitatory synaptic
transmission. Thus, fEPSPs observed 15–20 minutes after
application of DL-APV plus METH are significantly increased
to 1.146.04 [n=8(4)] (Fig. 2B, P,0.05). These changes in fEPSP
are similar to those evoked by METH alone (Fig. 1E), suggesting
that the METH-evoked increase in synaptic transmission we have
discovered is NMDA receptor independent.
Effects of methamphetamine on baseline synaptic
transmission and LTP are not altered by pre-application
of eticlopride (a dopamine D2-like receptor antagonist)
Since METH increases the concentration of extracellular
dopamine, serotonin, and norepinephrine [8], we considered the
likelihood that METH’s effects on baseline synaptic transmission
and/or LTP could be mediated via these receptor systems.
Interestingly, in the CA1 of rat hippocampus cocaine [31] and
GBR12935 [53] (drugs with increase the concentration of
extracellular monoamines) increase LTP by activation of D2-like
dopamine receptors. Therefore, we assessed whether a D2-like
receptor antagonist (eticlopride) could be effective in blocking the
effects of METH. We found that eticlopride (a D2-selective
receptor antagonist), at a concentration that effectively blocks a
representative experiments illustrating the average of fEPSPs 0–5 min prior to (solid line) and 55–60 min post-tetanus (dotted line, horizontal dashed
lines are 1 mV apart). At 0.1 mM METH, LTP was 1.586.08 [n=13(5)] (Fig. 1B); at 1 mM METH, LTP was 1.506.07 [n=13(7)] (Fig. 1C); at 10 mM METH,
LTP was 1.586.07 [n=14(8)] (Fig. 1D); at 30 mM METH, LTP was 1.376.06 [n=15(4)] (Fig. 1E); and at 60 mM METH, LTP was 1.326.24 [n=4(2)] (Fig. 1E).
(G) Concentration-response for the effect of METH on LTP magnitude. *=P,0.05, **=P,.01, ***=P,.001; different from drug free. Error
bars depict mean 6 SEM.
doi:10.1371/journal.pone.0011382.g001
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altered baseline synaptic transmission on its own, nor affected the
METH-mediated increase in synaptic transmission when co-
applied with METH. The normalized magnitude of fEPSPs 15–20
minutes after 1 mM eticlopride and 30 mM METH application
was significantly increased to 1.166.02 [n=4(4)] (Fig. 3B, t=50–
55 compared to t=70–75, P,0.05). D2-like dopamine receptor
blockade also did not attenuate the effects of METH on LTP. LTP
in the presence of eticlopride alone was 1.576.09 [n=3(3)], while
METH still decreased LTP in slices pretreated with eticlopride
(1.306.04, [n=4(4)] (Fig. 3A,B, P,0.05)).
SCH23390 (a D1-like receptor antagonist) increases
baseline synaptic transmission when applied alone
METH does not induce a further increase in synaptic
transmission or a decrease in LTP after SCH23390
pretreatment. D1/D5 receptor agonists can induce an LTP-
like potentiation in the CA1 area of the hippocampus [54,55].
Others have demonstrated that the application of D1/D5 agonist
increases LTP in the CA1 [56,57,58]. Since METH profoundly
increases the concentration of extracellular dopamine, it is feasible
that application of METH may have induced dopamine release to
mediate a dopamine-receptor dependent increase in baseline
synaptic transmission. To test the involvement of D1-like
dopamine receptors, we utilized D1/D5-selective dopamine
receptor antagonist SCH23390. Interestingly, SCH23390
increased baseline synaptic transmission when applied alone, an
effect not observed with shorter application times (5–10 minutes)
at the same concentration [56]. The magnitude of normalized
fEPSPs 15–20 minutes after 5 mM SCH23390 application was
1.126.03 [n=7(4)] (Fig. 4A, t=20–25 compared to t=40–45,
P,0.05). Furthermore, the addition of METH to the slices
pretreated with SCH23390 did not induce a further increase in
fEPSPs (Fig. 4B), suggesting that D1/D5 receptor activation is
Figure 2. METH-induced increase in synaptic transmission does not require stimulation, and is transient- returning to baseline
within and hour. Also, METH effects on baseline synaptic transmission are not dependent on NMDA receptors. (A) METH increase in synaptic
transmission is not long-lasting, and does not require stimulation. Summary plot of normalized fEPSP slope measurements recorded in the
CA1 region of the hippocampus. Results are from METH-treated slices. Stimulator turned off from t=15 to t=30. Error bars show 6 SEM. (B) The
effects of METH on baseline synaptic transmission are not altered by blockade of NMDA receptors. Summary plot of normalized fEPSP
slope measurements recorded in the CA1 region of the hippocampus. Result are from DL-APV + METH-treated slices. Error bars show 6 SEM.
doi:10.1371/journal.pone.0011382.g002
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transmission. Consistent with previous findings [59,60], we found
that blockade of D1/D5-like receptors with SCH23390 decreased
LTP. LTP was not significantly decreased by METH in slices
pretreated D1/D5 antagonist compared to slices treated with
SCH23390 alone. LTP in the presence of SCH23390 was
1.406.10 [n=7(4)], and 1.336.07 [n=8(4)] with SCH23390
plus METH (Fig. 4A,B).
METH-induced increase in baseline synaptic transmission
is attenuated in D1 receptor haploinsufficient mice
Since no known D1 or D5-selective receptor antagonists exist, in
order to further characterize the effects of METH, we utilized D1
and D5 receptor haploinsufficient mice. D1 or D5 dopamine
receptor knockout/haploinsufficient mice [61,62,63,64] have
eliminated/reduced D1 or D5 dopamine receptor expression,
respectively. We found that METH increased baseline synaptic
transmission in D5 receptor haploinsufficient mice only, and was
ineffective in D1 +/2 mice. Normalized fEPSPs were increased
15–20 minutes after 30 mM METH in D5 +/2 slices to 1.076.01
[n=6(3)] (Fig. 5D, P,0.05). Baseline synaptic transmission was
not significantly enhanced compared to 15–20 minutes after
METH in D1 receptor +/2 slices to 1.036.01 [n=9(5)] (Fig. 6B,
P,0.05). We also assessed LTP in D1 and D5 receptor
haploinsufficient mice under drug free and METH-exposed
conditions, finding no significant differences. LTP in drug free
D5 receptor +/2 mice was 1.276.07 [n=6(3)], while the addition
of METH had no significant effect, resulting in an LTP magnitude
Figure 3. The effects of METH on baseline synaptic transmission and LTP are not altered by pre-application eticlopride (a selective
D2-like dopamine receptor antagonist). (A,B) Summary plot of normalized fEPSP slope measurements recorded in the CA1 region of the
hippocampus. The red triangles (B) are from eticlopride (1 mM) and METH (30 mM) treated slices; the blue diamonds (A) show results from eticlopride
(1 mM) experiments. Error bars are 6 SEM. Insets are 30-msec sweeps taken from representative experiments illustrating the average fEPSP 0–5 min
prior to (solid line) and 55–60 min post-tetanus (dotted line, horizontal dashed lines are 1 mV apart).
doi:10.1371/journal.pone.0011382.g003
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from D1 receptor +/2 mice was 1.516.11 [n=9(5)], while the
magnitude of LTP in the presence of METH decreased to
1.336.08 [n=9(5)] in D1 +/2 slices (Fig. 5A,B).
5-HT1A serotonin antagonist NAN-190 blocks the effect
of METH on baseline synaptic transmission
We examined whether the effect of METH on baseline synaptic
transmission could have a serotonergic etiology, as well as a
dopaminergic component. A serotonergic mechanism for the
increase in baseline synaptic transmission is possible, since
serotonin can reduce inhibition of excitatory synaptic transmission
in the CA1 region of the hippocampus via activation of 5-HT1A
receptors [65]. We observed that pretreatment with serotonin 5-
HT1A competitive antagonist NAN-190 (0.5 mM) blocked the
effects of METH (30 mM) on synaptic transmission. The
magnitude of fEPSPs 15–20 minutes after NAN-190 and METH
application was 0.996.01 [n=6(4)] (Fig. 6B, t=50–55 compared
to t=70–75). These results suggest METH-mediated effects on
glutamatergic transmission can be modulated by the serotonergic
system in the hippocampus. It has been shown that the selective
serotonin reuptake inhibitor fluvoxamine, which increases extra-
synaptic serotonin, decreases LTP by a mechanism mediated by 5-
HT1A receptors [66]. To test whether the inhibitory effect of
METH on LTP also is mediated via activation of 5-HT1A
receptors, we measured METH-mediated decrease in LTP when
NAN-190 is co-applied. LTP in the presence of NAN-190
(0.5 mM) was 1.676.11 [n=8(6)], not significantly different from
LTP in METH (30 mM) slices pretreated with NAN-190
(1.516.06 [n=6(4)] (Fig. 6A,B)). This data suggests a seroto-
Figure 4. SCH23390 (a D1-like dopamine receptor antagonist) increases baseline synaptic transmission when applied alone. METH
does not induce a further increase in synaptic transmission or a decrease in LTP after SCH23390 pretreatment. (A,B) Summary plot of
normalized fEPSP slope measurements recorded in the CA1 region of the hippocampus. The red triangles (B) are from SCH23390 (5 mM) and METH
(30 mM) treated slices; the blue diamonds (A) show results from SCH23390 (5 mM) experiments. Error bars are 6 SEM. Insets are 30-msec sweeps taken
from representative experiments illustrating the average fEPSP 0–5 min prior to (solid line) and 55–60 min post-tetanus (dotted line, horizontal
dashed lines are 1 mV apart).
doi:10.1371/journal.pone.0011382.g004
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hippocampus.
Systemic METH exposure decreases LTP
In addition to the acute drug exposure experiments, we tested
the ability of METH to alter hippocampal synaptic plasticity in
mice exposed to systemic METH. It has been shown that i.p.
injection of METH decreases LTP of population spikes in CA1
[37], therefore we further assessed the effect of systemic METH
exposure on hippocampal function by examining LTP of synaptic
responses. Consistent with the acute-exposure studies, systemic
exposure of METH resulted in deficient LTP. In vehicle-injected
subjects, LTP was 1.436.05 [n=8(2)], whereas in METH-treated
mice LTP (assessed 16 hours after the last METH injection) was
significantly decreased to 1.226.07 [n=6(2)] (Fig. 7A). Stimula-
tion of the CA1 Schaffer collaterals in quick succession (from tens
to hundreds of milliseconds) results in the facilitation of the second
synaptic response [67]. This phenomena is referred to as paired-
pulse facilitation (PPF), and is thought to be due to an increase in
the probability of glutamate release [68,69] due to residual
presynaptic calcium [70,71,72,73]. Paired pulse facilitation was
not altered by METH exposure (Fig. 7B), suggesting systemic
METH does not induce a lasting change in the probability of
action-potential dependent presynaptic neurotransmitter release.
Discussion
The present study provides insight about the unique effects of
METH in the hippocampus. First, acute ex vivo application of
METH to hippocampal slices increases baseline synaptic trans-
mission, independent of NMDA receptor activation. Second, these
effects are mediated via activation of serotonergic and dopami-
nergic receptor systems (also see figure S1). Third, both systemic
and ex vivo METH decrease hippocampal LTP; the systemic results
in accord with a previous report from Dr. Chirwa’s lab [37]. These
findings contribute to our understanding of the impact of METH
on hippocampal function.
We found at 30 and 60 mM METH increased baseline synaptic
transmission in our preparation. This effect was not diminished by
the blockade of NMDA receptors with DL-APV, indicating the
observed increase in fEPSPs caused by METH is NMDA
receptor-independent. Interestingly, METH also increased fEPSPs
in the absence of stimulation (Fig. 2A). This may suggest the
increase in synaptic transmission we have observed is induced by
Figure 5.METH-induced increase in baseline synaptic transmissionis attenuated in D1receptorhaploinsufficientmice. (A,B) Summary
plot of normalized fEPSP slope measurements recorded in the CA1 region of the hippocampus of D1 +/2 mice. The red triangles (B) are from METH
(30 mM) treated slices; the blue diamonds (A) show results from drug-free experiments. Error bars are 6 SEM. Insets are 30-msec sweeps taken from
representative experiments illustrating the average fEPSP 0–5 min prior to (solid line) and 55–60 min post-tetanus (dotted line, horizontal dashed lines
are1 mVapart). (C,D) SummaryplotofnormalizedfEPSPslope measurementsrecordedin the CA1region of thehippocampus ofD5+/2 mice.Thered
triangles (B) are from METH (30 mM) treated slices; the blue diamonds (A) show results from drug-free experiments. Error bars are 6 SEM. Insets are
30-msec sweeps taken from representative experiments illustrating the average fEPSP 0–5 min prior to (solid line) and 55–60 min post-tetanus (dotted
line, horizontal dashed lines are 1 mV apart).
doi:10.1371/journal.pone.0011382.g005
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however, action potentials occur in hippocampal slices indepen-
dent of electrical stimulation [75,76,77]. Therefore we hypothesize
that while both modes (action-potential dependent and action-
potential independent) of monoamine release may occur in our
hippocampal slice preparation- it is the action-potential indepen-
dent mode of release that is primarily responsible for the effects of
METH we have observed. Future studies will unequivocally
discern whether action potentials are required for METH to
increase synaptic transmission. The increase in synaptic transmis-
sion we observed was not long lasting, returning to baseline within
,1 hour, and therefore is likely mechanistically dissimilar from
LTP. Short-lived decreases in synaptic efficacy caused by
dopamine, cocaine, and amphetamine have been observed in
the nucleus accumbens [78]. Although qualitatively different (a
decrease when we observed an increase), it is possible that the
increase in synaptic transmission in the hippocampus shares a
similar mechanism. Indeed, Nicola et al. [78] suggest that the
decrease in synaptic transmission in the accumbens is D1-receptor
mediated. Our results suggest a similar possibility.
Unlike our observed results with METH, cocaine can induce
both an increase and a decrease in hippocampal LTP, depending
on the concentration of acute cocaine applied [31,35]. The
decrease in LTP caused by cocaine at high concentrations may be
due to blockade of sodium channels [31]. Another DAT
antagonist, GBR12935, has been shown to increase LTP [53].
Thus, it was unexpected to measure a decrease in LTP mediated
by METH at lower concentrations, and we tentatively hypothe-
sized that METH may bidirectionally modulate LTP over a range
of concentrations. Contrary to our hypothesis, we never
Figure 6. 5-HT1A serotonin antagonist NAN-190 blocks the effect of METH on baseline synaptic transmission. (A,B) Summary plot of
normalized fEPSP slope measurements recorded in the CA1 region of the hippocampus. The red triangles (B) are from NAN-190 (0.5 mM) and METH
(30 mM) treated slices; the blue diamonds (A) show results from NAN-190 (0.5 mM) experiments. Error bars are 6 SEM. Insets are 30-msec sweeps
taken from representative experiments illustrating the average fEPSP 0–5 min prior to (solid line) and 55–60 min post-tetanus (dotted line, horizontal
dashed lines are 1 mV apart).
doi:10.1371/journal.pone.0011382.g006
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wide range of concentrations. Indeed, we observed a decrease in
LTP over a range of concentrations.
Recently it has been shown that eticlopride, a D2-receptor
antagonist, blocks a cocaine-induced increase in LTP, [31]. Our
findings indicate that, in contrast to cocaine, the effects of METH
are not mediated by the D2 dopamine receptor. As mentioned
previously, it is unclear why cocaine and METH, having a similar
pharmacological outcome (an increase in extracellular mono-
amines), have different effects on synaptic plasticity apparently
mediated by different receptor systems. Indeed, the ‘cocaine
paradox’ [79], in which monoamine neurotransmitter transporter
blockers (e.g., cocaine, GBR12935) curiously reduce the effect of
transporter substrates, or releasers (e.g., methamphetamine, am-
phetamine), elegantly demonstrates that METH-exposure results in
a higher extrasynaptic concentration of monoamines than drugs
which block monoamine neurotransmitter transporters. Why then,
do we not simply see the same effects, only larger, induced by
METH vs. DAT blockers? One possible explanation is that the
larger sphere and duration of monoaminergic influence, or volume
transmission [80] induced by METH exposure may activate
different subsets of receptors. Another intriguing speculation is that
cocaine and METH may have differing activity at sigma receptors,
indeed, sigma receptor agonists can decrease LTP in the CA1 [81].
As previously reported, we also observed that the D1/D5
dopamine antagonist SCH23390 decreases LTP per se [59]. Our
surprising finding that SCH23390 on its own increased baseline
synaptic transmission might be explained by our longer drug
treatment protocol before the tetanus stimulation (30 min)
compared to previously published observations [54,56]. The
finding that application of METH after pre-application of
SCH23390 did not increase in baseline synaptic transmission
Figure 7. In vivo METH exposure also decreases LTP. (A) Summary plot of normalized fEPSP slope measurements recorded in the CA1 region of
the hippocampus. The red triangles are from METH-treated mice; the blue diamonds show results from vehicle-treated subjects. Error bars are 6 SEM.
(B) Summary plot of paired-pulse facilitation measurements recorded in the CA1 region of the hippocampus. The red triangles are from METH-treated
mice; the blue diamonds show results from vehicle-treated subjects. Error bars are 6 SEM.
doi:10.1371/journal.pone.0011382.g007
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fEPSPs might in part be due to the release of endogenous
dopamine and subsequent activation of D1/D5-like receptors (also
see figure S1). Application of D1/D5 agonists can induce a
potentiation that is long lasting, D1/D5 receptor specific, and
requires protein synthesis and glutamatergic activation [47],
although some have not observed this phenomenon [55]. The
short duration of the increase in fEPSPs induced by METH
indicates it is likely not similar to the long-lasting D1/D5 agonist
potentiation others have observed [54].
Since no known D1 or D5-selective pharmacological tools
currently exist, D1 and D5 haploinsufficient mice are attractive
tools to further characterize the putative dopaminergic effects of
METH. In addition, a haploinsufficient genotype is a more
generalizable condition to human pathophysiology than complete
knockout of a protein [82]. The finding that METH increased
baseline synaptic transmission only in D5 receptor haploinsuffi-
cient mice suggests that the effects of METH in part may rely on
D1-like dopamine receptors, and in addition, specifically implicate
the D1 receptor in the effects of METH on baseline synaptic
transmission. Although LTP has been assessed in D1 receptor
knockout mice [83], to our knowledge synaptic plasticity has not
been studied in either D1 or D5 haploinsufficient mice, thus, our
results provide additional information about the modulatory
effects of D1 and D5 receptors on LTP. To our knowledge, we
are first to show a deficit in LTP in D5 receptor +/2 mice,
suggesting that the D5 receptor is required for the normal
expression of synaptic plasticity.
Our findings that METH-evoked effects on synaptic transmission
and LTP are reduced by a 5-HT1A antagonist, NAN-190 implicate
a serotonergic mechanism for METH in the hippocampus. The
reported effects of 5-HT in the hippocampus are divergent, as some
have documented inhibitory [84,85,86], while others have shown
excitatory[65]effects,ornoeffectonsynaptictransmission[87].Our
results suggest that 5-HT has an excitatory effect in the CA1 (also see
figure S1). One documented mechanism for excitatory effects of 5-
HT in the hippocampus suggests 5-HT1A receptor activation can
inhibit tonic GABA release from inhibitory interneurons, thereby
inhibiting glutamatergic transmission [65]. Future studies are
required to further examine this putative METH-induced seroto-
nergic modulation of hippocampal neurotransmission.
Our studies on the systemic exposure of animals to METH also
demonstrated a decrease in LTP. We observed no change in
paired-pulse facilitation, which suggests that there is not a change
in the probability of transmitter release caused by systemic METH
administration. It is of interest to note that the half-life of METH
in mice is ,1 hour [88,89,90], much shorter than in humans
[12,91,92]. We assessed the LTP ,16 hours after the last
injection. Using a t1/2 of 70 minutes, the elimination rate
constant can be easily calculated (t1/2=ln(2)/k). Assuming
instantaneous absorption, we estimated of the percent of drug
plasma concentration remaining after sixteen half-lives using first
order kinetics with concentration of drug at time zero being equal
to 100% (C(0)=100%) using the equation Ct=C (0)e
2kt (C=
concentration, e=2.7183, k=elimination rate constant, t=time).
This estimate (which does not account for i.p. absorption),
indicates that after 16 hours, the percentage of the initial
concentration of METH remaining would be 0.0074%. We
estimate that nearly all of the METH from the last i.p. injection
was cleared at the time the mice were sacrificed for LTP
experiments [92]. This suggests that METH has a lasting effect on
synaptic plasticity after the drug is cleared from the body. It is
unknown how long the effect of METH on LTP will last, or if it
will remain qualitatively similar, since bi-directional modulation of
synaptic plasticity by drugs of abuse (cocaine) has been observed
after long periods of withdrawal [24]. This is an important
question, and will be further studied.
In summary, we provide evidence that METH increases
baseline synaptic transmission (before high frequency tetanus see
Fig. 1E,F; time=30–40 min) and decreases the magnitude of
LTP induced by a high frequency tetanus event. We propose a
dopaminergic and serotonergic mechanism for the effect of
METH on fEPSPs. Our results also suggest that the D1 dopamine
receptor may be specifically involved in the effect of METH on
synaptic transmission. We hypothesize that deficient hippocampal
synaptic plasticity may be a hallmark of METH-induced adverse
cognitive/addictive processes.
Supporting Information
Figure S1 Application of dopamine (DA), or serotonin (5-HT)
increases baseline synaptic transmission. (A) Summary plot of
normalized fEPSP slope measurements recorded in the CA1
region of the hippocampus. Green circles show results from
dopamine-treated slices, purple squares are from serotonin-treated
slices. Error bars show 6 SEM, no tetanus was given.
Found at: doi:10.1371/journal.pone.0011382.s001 (0.63 MB TIF)
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